PMID- 30157036
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20200213
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Linking)
VI  - 30
IP  - 4
DP  - 2019 Jun
TI  - Chronic clozapine treatment improves the alterations of prepulse inhibition and 
      BDNF mRNA expression in the medial prefrontal cortex that are induced by 
      adolescent social isolation.
PG  - 311-319
LID - 10.1097/FBP.0000000000000419 [doi]
AB  - Isolation rearing produces significant behavioral and neurochemical dysfunctions 
      in rodents, which resemble the symptoms of schizophrenia. Clozapine, one of the 
      atypical antipsychotics, is widely used in the treatment of schizophrenia 
      patients and in experimental studies. In this study, male Sprague Dawley rats 
      were randomly assigned to either group-reared or isolation-reared conditions 
      during postnatal days (PNDs) 21-34. During PNDs 46-55, the rats were subjected to 
      chronic clozapine (1.0 mg/kg for 10 days) or saline treatment. On PND 56, all 
      rats underwent behavioral testing and then were sacrificed for biochemical 
      testing. The results indicated that adolescent social isolation induced 
      impairments in prepulse inhibition and reversal learning, and clozapine injection 
      improved the prepulse inhibition disruption but not reversal learning ability. 
      Furthermore, clozapine administration reversed the increased brain-derived 
      neurotrophic factor (BDNF) mRNA level in the medial prefrontal cortex (mPFC) that 
      was induced by adolescent isolation. However, clozapine decreased the BDNF mRNA 
      level in the mPFC in group-reared rats. Together, our findings provide additional 
      evidence that a low dose of chronic clozapine treatment could improve information 
      filtering/sensorimotor gating and alterations in the BDNF mRNA level in the mPFC 
      induced by adolescent social isolation.
FAU - Li, Man
AU  - Li M
AD  - Department of Psychology.
AD  - Academy of Psychology and Behavior, Tianjin Normal University.
AD  - Center of Collaborative Innovation for Assessment and Promotion of Mental Health, 
      Tianjin.
FAU - Wang, Weiwen
AU  - Wang W
AD  - Key laboratory of Mental Health, Institute of Psychology, Chinese Academy of 
      Sciences, Beijing, China.
FAU - Sun, Lan
AU  - Sun L
AD  - School of Psychological and Cognitive Science, Beijing Key Laboratory of Behavior 
      and Mental Health, Peking University.
FAU - Du, Wei
AU  - Du W
AD  - School of Psychological and Cognitive Science, Beijing Key Laboratory of Behavior 
      and Mental Health, Peking University.
FAU - Zhou, Hao
AU  - Zhou H
AD  - School of Psychological and Cognitive Science, Beijing Key Laboratory of Behavior 
      and Mental Health, Peking University.
FAU - Shao, Feng
AU  - Shao F
AD  - School of Psychological and Cognitive Science, Beijing Key Laboratory of Behavior 
      and Mental Health, Peking University.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Bdnf protein, rat)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - J60AR2IKIC (Clozapine)
SB  - IM
MH  - Animals
MH  - Antipsychotic Agents/pharmacology
MH  - Brain-Derived Neurotrophic Factor/genetics/metabolism
MH  - Clozapine/*pharmacology
MH  - Disease Models, Animal
MH  - Gene Expression/drug effects
MH  - Learning/drug effects
MH  - Male
MH  - Prefrontal Cortex/drug effects/metabolism
MH  - Prepulse Inhibition/*drug effects
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reflex, Startle/drug effects
MH  - Reversal Learning/drug effects
MH  - Schizophrenia/*drug therapy/physiopathology
MH  - Social Isolation/psychology
EDAT- 2018/08/30 06:00
MHDA- 2020/02/14 06:00
CRDT- 2018/08/30 06:00
PHST- 2018/08/30 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
PHST- 2018/08/30 06:00 [entrez]
AID - 10.1097/FBP.0000000000000419 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2019 Jun;30(4):311-319. doi: 10.1097/FBP.0000000000000419.